We have previously shown that traditionally formulated MS liposomes with encapsulated ovalbumin (MS–OVA) induced OVA-CD8+ T cell responses and delayed the progression of the solid B16-OVA melanoma tumor [8,15]. This evidence concerns the gene CD8A and melanoma.